Home » Orphan Drug Designation Granted to SK Biopharmaceuticals’ Carisbamate for the Management of Infantile Spasms
Orphan Drug Designation Granted to SK Biopharmaceuticals’ Carisbamate for the Management of Infantile Spasms
SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that it was granted special status by the FDA for carisbamate for the management of patients with infantile spasms, a form of epilepsy associated with increased risk of death or mental retardation.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May